학술논문
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Document Type
Article
Author
Vistisen, D.; Carstensen, B.; Elisabetta, P.; Lanzinger, S.; Holl, R.W.; Tan, E.C.-H.; Yabe, D.; Kim, D.J.; Ha, K.H.; Sheu, W.H.-H.; Melzer-Cohen, C.; Karasik, A.; Núñez, J.; Halvorsen, S.; Langslet, G.; Nyström, T.; Niskanen, L.; Guleria, S.; Klement, R.; Carrasco, M.; Foersch, J.; Farsani, S.F.; Shay, C.; Koeneman, L.; Hoti, F.; Khunti, K.; Zaccardi, F.; Subramanian, A.; Nirantharakumar, K.
Source
In: Cardiovascular Diabetology . (Cardiovascular Diabetology, December 2023, 22(1))
Subject
Language
English
ISSN
14752840